Related Experiment Video
Updated: Jul 16, 2025

Phenotypic Characterization of Macrophages from Rat Kidney by Flow Cytometry
Published on: October 18, 2016
Overreactive macrophages in SARS-CoV-2 infection: The effects of ACEI
Dominik Felkle1, Katarzyna Zięba1, Konrad Kaleta1
1Students' Scientific Group at the Department of Immunology, Jagiellonian University Medical College, Czysta 18, 31-121 Kraków, Poland.
Abstract:
Among various factors influencing the course of SARS-CoV-2 infection in humans, macrophage overactivation is considered the main cause of the cytokine storm that leads to severe complications of COVID-19. Moreover, the increased expression of angiotensin converting enzyme 2 (ACE2), an obligatory entry receptor of the coronavirus, caused by treatment with ACE inhibitors (ACEI) lowered overall confidence in the safety of these drugs. However, analysis of the course of coronavirus infection in patients treated with ACEI does not support these concerns. Instead, the beneficial effect of ACEI on macrophages has increasingly been emphasized. This includes their anti-inflammatory activation and the consequent reduction in the risk of severe disease and life-threatening complications. Herein, we summarize the current knowledge and understanding of the dual role of macrophages in SARS-CoV-2 infection, with a special focus on the postulated mechanisms underlying the beneficial effects of macrophage targeting by ACEI. These seem to involve the stimulation of macrophage angiotensin II type 2 and Mas receptors by angiotensin 1-7, intensively produced due to the up-regulation of ACE2 expression on macrophages, as well as the direct inhibition of macrophage hyper-responsiveness by ACEI. The impact of ACEI on macrophages may also lead to the activation of an effective antiviral response due to the increased expression of ACE2.
Insights
Angiotensin-converting enzyme inhibitors (ACEI) may benefit COVID-19 patients by modulating macrophage activity, reducing severe disease risk. These drugs appear to mitigate the cytokine storm, offering a protective effect against severe SARS-CoV-2 complications.
Area of Science:
- Immunology
- Pharmacology
- Virology
Background:
- Macrophage overactivation drives the cytokine storm in severe COVID-19.
- Concerns existed regarding ACE inhibitors (ACEI) due to increased ACE2 expression, a SARS-CoV-2 receptor.
- Clinical observations suggest ACEI may be safe and beneficial in COVID-19 patients.
Purpose of the Study:
- To review the dual role of macrophages in SARS-CoV-2 infection.
- To elucidate the mechanisms behind the beneficial effects of ACEI on macrophages.
- To explore how ACEI impacts macrophage response and COVID-19 severity.
Main Methods:
- Review of current knowledge on macrophage function in COVID-19.
- Analysis of the impact of ACE inhibitors on macrophage activation.
- Examination of molecular pathways involving ACE2, angiotensin-(1-7), and macrophage receptors.
Main Results:
- ACEI demonstrate beneficial effects on macrophages, promoting anti-inflammatory activation.
- ACEI may reduce the risk of severe COVID-19 and life-threatening complications.
- Proposed mechanisms include stimulation of angiotensin II type 2 and Mas receptors by angiotensin-(1-7) and direct inhibition of macrophage hyper-responsiveness.
Conclusions:
- ACEI may exert protective effects in SARS-CoV-2 infection by modulating macrophage responses.
- Targeting macrophages with ACEI could be a therapeutic strategy to mitigate COVID-19 severity.
- Increased ACE2 expression on macrophages due to ACEI may enhance antiviral responses.
Related Concept Videos
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure II: Pathophysiology
Antihypertensive Drugs: Action of β1 Blockers

